Nacuity Entered into an Exclusive License Agreement with Arctic to Develop and Commercialize NPI-001 in Iceland
Shots:
- Arctic to get an exclusive right to develop & commercialize NPI-001 for HCCAA in Iceland & related CAAs globally. The companies collaborated for all regulatory approval and development activities related to NPI-001 for HCCAA
- The collaboration helps to advance NPI-001 for HCCAA & other related forms of amyloid angiopathies (CAAs) globally. The companies also focused to develop therapies that stop oxidative tissue damage
- NPI-001 is a differentiated, purified, GMP-grade NACA that is being developed to treat a wide range of diseases & conditions linked to oxidative stress and low glutathione levels. The therapy has received ODD from the US FDA for RP in Usher Syndrome & is being studied in P-I/II trial for Usher Syndrome
Ref: Globenewswire | Image: Nacuity
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
